The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.
A user's 2.5 year transformation of using 0.5mg finasteride and RU58841 to combat hair loss, with the possibility of increasing the RU for further regrowth.
Hair loss concerns and treatments like Minoxidil and Finasteride are humorously discussed. The community's quirks and dedication to battling hair loss are highlighted.
User experienced hair regrowth with minoxidil and dermarolling for 3 months. Routine includes applying 1ml minoxidil nightly and dermarolling with 0.5mm needles twice a week.
User experienced side effects from oral finasteride and tried topical Alfatradiol for hair loss. Alfatradiol provided maintenance without significant regrowth, and user suggests it as an alternative for those struggling with finasteride side effects.
A user shared their 2-month progress on finasteride 1mg daily and weekly derma rolling, showing noticeable hair regrowth. Replies confirm visible improvement, though some attribute it partially to lighting.
The conversation discusses a 4-month hair regrowth protocol that includes finasteride (1.25mg), RU58841, dermarolling, ketoconazole, minoxidil, peppermint oil, and fatty acids/oils. Progress pictures are shared to show the results of these treatments.
Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.
A user had a failed hair transplant with 2800 FUE grafts at a clinic in Turkey, where finasteride was used, and the procedure was poorly executed by technicians rather than the main surgeon. The user later sought repair from a more experienced doctor, highlighting issues with large clinics that handle multiple patients daily.
RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.
SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.
The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.
The conversation is about a user's hair regrowth progress using topical minoxidil, with plans to start finasteride. The user also takes Vitamin D and washes their hair 2-3 times a week.
Hair loss treatments, including Alfatradiol, Minoxidil, Finasteride, and RU58841. It discusses the efficacy of these treatments for hair growth and regrowth.
A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.
The conversation is about hair regrowth results after two months using oral finasteride, oral and topical minoxidil, and weekly dermarolling. The user shared before and after photos to show progress.
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.
RU58841 and Minoxidil can cause heart-related side effects like chest pain and heart racing. Pyrilutamide is suggested as a safer alternative, though it's new and costly.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.
The conversation discusses a transgender individual's successful hair loss treatment over 1.5 years using 2.5mg oral minoxidil, 5mg finasteride, and 8mg weekly injectable estradiol valerate. Some users debate the appropriateness of this approach within the group's goals, while others support the individualized treatment and its additional benefits for transgender individuals.
Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.
The conversation is about finding a reputable place to buy Clascoterone in the US. An alternative treatment, pyrilutamide, is suggested as a strong and official option.
GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.
RU58841 and pyrilutamide are being discussed as potential hair loss treatments, with some users reporting side effects. There is interest in these treatments as alternatives to 5ar inhibitors and oral minoxidil due to concerns about safety and side effects.
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.